Targeted Genetics Reports Data From HIV/AIDS Vaccine Trial

Targeted Genetics presented interim data from a Phase II African trial of tgAAC09, its HIV/AIDS vaccine candidate.

TgAAC09 uses an adeno-associated virus vector to deliver genes encoding HIV proteins and is designed to stimulate an immune response against the disease, according to Targeted Genetics.

In this double-blind, randomized, placebo-controlled study, 91 healthy HIV-negative volunteers at five clinical sites in Africa have received two intra-muscular injections of placebo or tgAAC09 at three different dosage levels either six or 12 months apart, the company added.

According to the company, the reported safety data reflect results following the first vaccination and revaccination in 91 and 82 volunteers, respectively. The vaccine has been well-tolerated, and no severe local or systemic reactions to vaccination have been reported.